Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyIbandronate
Identification
- Name
- Ibandronate
- Accession Number
- DB00710 (APRD00231, DB04635)
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Description
Ibandronate is a nitrogen-containing bisphosphonate in the same class as alendronate and risedronate. Ibandronate inhibits osteoclast-mediated bone resorption. All of the bisphosphonates prevent the breakdown of bone by bone cells called osteoclasts. In persons who are at high risk for osteoporosis, bisphosphonates not only result in increased amounts of bone and bone strength, they also reduce the risk of hip fractures and other bone fractures.
- Structure
Structure for DB00710 (Ibandronate)
- Synonyms
- Ibandronic Acid
- External IDs
- R484
- Product Ingredients
Ingredient UNII CAS InChI Key Ibandronate sodium 23Y0B94E49 138926-19-9 LXLBEOAZMZAZND-UHFFFAOYSA-M - Product Images
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Bondronat Liquid 1 mg Intravenous Hoffmann La Roche 2004-05-31 2006-05-17 Canada 
Boniva Tablet, film coated 150 mg/1 Oral Physicians Total Care, Inc. 2005-06-02 Not applicable US 
Boniva Injection, solution 3 mg/3mL Intravenous Genentech, Inc. 2011-06-01 Not applicable US Boniva Tablet, film coated 150 mg/1 Oral Genentech, Inc. 2002-07-15 Not applicable US Bonviva Injection, solution 3 mg Intravenous Atnahs Pharma Uk Limited 2004-02-23 Not applicable EU 
Bonviva Tablet, film coated 150 mg Oral Atnahs Pharma Uk Limited 2004-02-23 Not applicable EU Bonviva Injection, solution 3 mg Intravenous Atnahs Pharma Uk Limited 2004-02-23 Not applicable EU Bonviva Tablet, film coated 150 mg Oral Atnahs Pharma Uk Limited 2004-02-23 Not applicable EU - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Iasibon Tablet, film coated 50 mg Oral Pharmathen S.A. 2011-01-21 Not applicable EU Iasibon Injection, solution, concentrate 6 mg Intravenous Pharmathen S.A. 2011-01-21 Not applicable EU Iasibon Tablet, film coated 50 mg Oral Pharmathen S.A. 2011-01-21 Not applicable EU Iasibon Injection, solution, concentrate 6 mg Intravenous Pharmathen S.A. 2011-01-21 Not applicable EU Iasibon Injection, solution, concentrate 2 mg Intravenous Pharmathen S.A. 2011-01-21 Not applicable EU Iasibon Tablet, film coated 50 mg Oral Pharmathen S.A. 2011-01-21 Not applicable EU Iasibon Tablet, film coated 50 mg Oral Pharmathen S.A. 2011-01-21 Not applicable EU Iasibon Injection, solution, concentrate 6 mg Intravenous Pharmathen S.A. 2011-01-21 Not applicable EU Iasibon Injection, solution, concentrate 1 mg Intravenous Pharmathen S.A. 2011-01-21 Not applicable EU Iasibon Tablet, film coated 50 mg Oral Pharmathen S.A. 2011-01-21 Not applicable EU - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Bondenza Ibandronate (150 mg) Tablet, film coated Oral Roche Registration Limited 2004-02-23 2013-05-13 EU Bondenza Ibandronate (3 mg) Injection, solution Intravenous Roche Registration Limited 2004-02-23 2013-05-13 EU Bondenza Ibandronate (150 mg) Tablet, film coated Oral Roche Registration Limited 2004-02-23 2013-05-13 EU Bondenza Ibandronate (3 mg) Injection, solution Intravenous Roche Registration Limited 2004-02-23 2013-05-13 EU - International/Other Brands
- ADRONiL / Bondronat / Bonviva
- Categories
- UNII
- UMD7G2653W
- CAS number
- 114084-78-5
- Weight
- Average: 319.2289
Monoisotopic: 319.094975119 - Chemical Formula
- C9H23NO7P2
- InChI Key
- MPBVHIBUJCELCL-UHFFFAOYSA-N
- InChI
- InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)
- IUPAC Name
- {1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl}phosphonic acid
- SMILES
- CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O
Pharmacology
- Indication
For the treatment and prevention of osteoporosis in postmenopausal women.
- Structured Indications
- Pharmacodynamics
Ibandronate is a nitrogen-containing bisphosphonate in the same class as alendronate and risedronate. Ibandronate inhibits osteoclast-mediated bone resorption. All of the bisphosphonates prevent the breakdown of bone by bone cells called osteoclasts. In persons who are at high risk for osteoporosis, bisphosphonates not only result in increased amounts of bone and bone strength, they also reduce the risk of hip fractures and other bone fractures.
- Mechanism of action
The action of ibandronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Nitrogen-containing bisphosphonates (such as pamidronate, alendronate, risedronate, ibandronate and zoledronate) appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting farnesyl pyrophosphate (FPP) synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.
Target Actions Organism AFarnesyl pyrophosphate synthase inhibitorHuman AHydroxylapatite antagonistHuman - Absorption
Poorly absorbed (mean bioavailability following a 2.5 mg oral dose is about 0.6% compared to intravenous dosing). Absorption is impaired by any kind of food or drink other than plain water.
- Volume of distribution
- 90 L
- Protein binding
90.9 to 99.5% over an ibandronate concentration range of 2 to 10 ng/mL
- Metabolism
No evidence of ibandronate being metabolized in humans.
- Route of elimination
Ibandronate is eliminated by renal excretion. Unabsorbed ibandronate is eliminated unchanged in the feces.
- Half life
10-60 hours
- Clearance
- 84 to 160 mL/min [IV administration]
- Toxicity
LD50 = 811 mg/kg (rat, oral), side effects include bronchitis, pneumonia and urinary tract infections.
- Affected organisms
- Humans and other mammals
- Pathways
Pathway Category Ibandronate Action Pathway Drug action - Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group (4R)-limonene The risk or severity of adverse effects can be increased when (4R)-limonene is combined with Ibandronate. Investigational Aceclofenac The risk or severity of adverse effects can be increased when Aceclofenac is combined with Ibandronate. Approved, Investigational Acemetacin The risk or severity of adverse effects can be increased when Acemetacin is combined with Ibandronate. Approved, Experimental, Investigational Acetylsalicylic acid The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Ibandronate. Approved, Vet Approved Aclarubicin Aclarubicin may increase the hypocalcemic activities of Ibandronate. Investigational Adapalene The risk or severity of adverse effects can be increased when Adapalene is combined with Ibandronate. Approved Alclofenac The risk or severity of adverse effects can be increased when Alclofenac is combined with Ibandronate. Approved, Withdrawn Aldoxorubicin Aldoxorubicin may increase the hypocalcemic activities of Ibandronate. Investigational Almasilate The serum concentration of Ibandronate can be decreased when it is combined with Almasilate. Approved, Experimental Alminoprofen The risk or severity of adverse effects can be increased when Alminoprofen is combined with Ibandronate. Experimental Aloglutamol The serum concentration of Ibandronate can be decreased when it is combined with Aloglutamol. Approved Aluminium The serum concentration of Ibandronate can be decreased when it is combined with Aluminium. Approved, Investigational Aluminium acetoacetate The serum concentration of Ibandronate can be decreased when it is combined with Aluminium acetoacetate. Experimental Aluminium glycinate The serum concentration of Ibandronate can be decreased when it is combined with Aluminium glycinate. Experimental Aluminum hydroxide The serum concentration of Ibandronate can be decreased when it is combined with Aluminum hydroxide. Approved, Investigational Amikacin Amikacin may increase the hypocalcemic activities of Ibandronate. Approved, Investigational, Vet Approved Amiodarone Ibandronate may increase the QTc-prolonging activities of Amiodarone. Approved, Investigational Amrubicin Amrubicin may increase the hypocalcemic activities of Ibandronate. Approved, Investigational Anagrelide Ibandronate may increase the QTc-prolonging activities of Anagrelide. Approved Andrographolide The risk or severity of adverse effects can be increased when Andrographolide is combined with Ibandronate. Investigational Anisodamine The risk or severity of adverse effects can be increased when Anisodamine is combined with Ibandronate. Investigational Annamycin Annamycin may increase the hypocalcemic activities of Ibandronate. Investigational Antipyrine The risk or severity of adverse effects can be increased when Antipyrine is combined with Ibandronate. Approved, Investigational Apocynin The risk or severity of adverse effects can be increased when Apocynin is combined with Ibandronate. Investigational Apramycin Apramycin may increase the hypocalcemic activities of Ibandronate. Experimental, Vet Approved Apremilast The risk or severity of adverse effects can be increased when Apremilast is combined with Ibandronate. Approved, Investigational Arbekacin Arbekacin may increase the hypocalcemic activities of Ibandronate. Approved, Investigational Arsenic trioxide Ibandronate may increase the QTc-prolonging activities of Arsenic trioxide. Approved, Investigational Artemether Ibandronate may increase the QTc-prolonging activities of Artemether. Approved Asenapine Ibandronate may increase the QTc-prolonging activities of Asenapine. Approved Azapropazone The risk or severity of adverse effects can be increased when Azapropazone is combined with Ibandronate. Withdrawn Azelastine The risk or severity of adverse effects can be increased when Azelastine is combined with Ibandronate. Approved Azithromycin Ibandronate may increase the QTc-prolonging activities of Azithromycin. Approved Balsalazide The risk or severity of adverse effects can be increased when Balsalazide is combined with Ibandronate. Approved, Investigational Bedaquiline Ibandronate may increase the QTc-prolonging activities of Bedaquiline. Approved Bekanamycin Bekanamycin may increase the hypocalcemic activities of Ibandronate. Experimental Bendazac The risk or severity of adverse effects can be increased when Bendazac is combined with Ibandronate. Experimental Benorilate The risk or severity of adverse effects can be increased when Benorilate is combined with Ibandronate. Experimental Benoxaprofen The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Ibandronate. Withdrawn Benzydamine The risk or severity of adverse effects can be increased when Benzydamine is combined with Ibandronate. Approved Bevonium The risk or severity of adverse effects can be increased when Bevonium is combined with Ibandronate. Experimental Bismuth Subcitrate The serum concentration of Ibandronate can be decreased when it is combined with Bismuth Subcitrate. Approved, Investigational Bismuth subnitrate The serum concentration of Ibandronate can be decreased when it is combined with Bismuth subnitrate. Approved, Experimental Bromfenac The risk or severity of adverse effects can be increased when Bromfenac is combined with Ibandronate. Approved Bucillamine The risk or severity of adverse effects can be increased when Bucillamine is combined with Ibandronate. Investigational Bufexamac The risk or severity of adverse effects can be increased when Bufexamac is combined with Ibandronate. Approved, Experimental Bumadizone The risk or severity of adverse effects can be increased when Bumadizone is combined with Ibandronate. Experimental Calcium Acetate The serum concentration of Ibandronate can be decreased when it is combined with Calcium Acetate. Approved, Investigational Calcium Carbonate The serum concentration of Ibandronate can be decreased when it is combined with Calcium Carbonate. Approved, Investigational Calcium Chloride The serum concentration of Ibandronate can be decreased when it is combined with Calcium Chloride. Approved Calcium Citrate The serum concentration of Ibandronate can be decreased when it is combined with Calcium Citrate. Approved Calcium glubionate The serum concentration of Ibandronate can be decreased when it is combined with Calcium glubionate. Approved Calcium Gluceptate The serum concentration of Ibandronate can be decreased when it is combined with Calcium Gluceptate. Approved Calcium gluconate The serum concentration of Ibandronate can be decreased when it is combined with Calcium gluconate. Approved, Vet Approved Calcium lactate The serum concentration of Ibandronate can be decreased when it is combined with Calcium lactate. Approved, Experimental, Investigational, Vet Approved Calcium lactate gluconate The serum concentration of Ibandronate can be decreased when it is combined with Calcium lactate gluconate. Experimental Calcium levulinate The serum concentration of Ibandronate can be decreased when it is combined with Calcium levulinate. Approved, Experimental Calcium pangamate The serum concentration of Ibandronate can be decreased when it is combined with Calcium pangamate. Experimental Calcium Phosphate The serum concentration of Ibandronate can be decreased when it is combined with Calcium Phosphate. Approved Calcium silicate The serum concentration of Ibandronate can be decreased when it is combined with Calcium silicate. Experimental Carbaspirin calcium The risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Ibandronate. Experimental, Investigational Carprofen The risk or severity of adverse effects can be increased when Carprofen is combined with Ibandronate. Approved, Vet Approved, Withdrawn Casein The serum concentration of Ibandronate can be decreased when it is combined with Casein. Approved Castanospermine The risk or severity of adverse effects can be increased when Castanospermine is combined with Ibandronate. Experimental Celecoxib The risk or severity of adverse effects can be increased when Celecoxib is combined with Ibandronate. Approved, Investigational Ceritinib Ibandronate may increase the QTc-prolonging activities of Ceritinib. Approved Chloroquine The risk or severity of adverse effects can be increased when Chloroquine is combined with Ibandronate. Approved, Investigational, Vet Approved Chlorpromazine Ibandronate may increase the QTc-prolonging activities of Chlorpromazine. Approved, Investigational, Vet Approved Choline magnesium trisalicylate The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Ibandronate. Approved Ciprofloxacin Ibandronate may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Investigational Cisapride Ibandronate may increase the QTc-prolonging activities of Cisapride. Approved, Investigational, Withdrawn Citalopram Ibandronate may increase the QTc-prolonging activities of Citalopram. Approved Clarithromycin Ibandronate may increase the QTc-prolonging activities of Clarithromycin. Approved Clonixin The risk or severity of adverse effects can be increased when Clonixin is combined with Ibandronate. Approved Clozapine Ibandronate may increase the QTc-prolonging activities of Clozapine. Approved Crizotinib Ibandronate may increase the QTc-prolonging activities of Crizotinib. Approved Curcumin The risk or severity of adverse effects can be increased when Curcumin is combined with Ibandronate. Approved, Investigational Daunorubicin Daunorubicin may increase the hypocalcemic activities of Ibandronate. Approved Deferasirox The risk or severity of adverse effects can be increased when Ibandronate is combined with Deferasirox. Approved, Investigational Dexlansoprazole The therapeutic efficacy of Ibandronate can be decreased when used in combination with Dexlansoprazole. Approved, Investigational Dexrabeprazole The therapeutic efficacy of Ibandronate can be decreased when used in combination with Dexrabeprazole. Experimental Dibekacin Dibekacin may increase the hypocalcemic activities of Ibandronate. Experimental Diclofenac The risk or severity of adverse effects can be increased when Diclofenac is combined with Ibandronate. Approved, Vet Approved Difenpiramide The risk or severity of adverse effects can be increased when Difenpiramide is combined with Ibandronate. Experimental Diflunisal The risk or severity of adverse effects can be increased when Diflunisal is combined with Ibandronate. Approved, Investigational Dihydrostreptomycin Dihydrostreptomycin may increase the hypocalcemic activities of Ibandronate. Investigational, Vet Approved Disopyramide Ibandronate may increase the QTc-prolonging activities of Disopyramide. Approved Dofetilide Ibandronate may increase the QTc-prolonging activities of Dofetilide. Approved, Investigational Dolasetron Ibandronate may increase the QTc-prolonging activities of Dolasetron. Approved, Investigational Domperidone Ibandronate may increase the QTc-prolonging activities of Domperidone. Approved, Investigational, Vet Approved Doxorubicin Doxorubicin may increase the hypocalcemic activities of Ibandronate. Approved, Investigational Dronedarone Ibandronate may increase the QTc-prolonging activities of Dronedarone. Approved Droperidol Ibandronate may increase the QTc-prolonging activities of Droperidol. Approved, Vet Approved Droxicam The risk or severity of adverse effects can be increased when Droxicam is combined with Ibandronate. Withdrawn Duvelisib The risk or severity of adverse effects can be increased when Duvelisib is combined with Ibandronate. Investigational E-6201 The risk or severity of adverse effects can be increased when E-6201 is combined with Ibandronate. Investigational Eliglustat Ibandronate may increase the QTc-prolonging activities of Eliglustat. Approved Epirizole The risk or severity of adverse effects can be increased when Epirizole is combined with Ibandronate. Approved Epirubicin Epirubicin may increase the hypocalcemic activities of Ibandronate. Approved Erythromycin Ibandronate may increase the QTc-prolonging activities of Erythromycin. Approved, Investigational, Vet Approved Escitalopram Ibandronate may increase the QTc-prolonging activities of Escitalopram. Approved, Investigational Esomeprazole The therapeutic efficacy of Ibandronate can be decreased when used in combination with Esomeprazole. Approved, Investigational Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Ibandronate. Approved, Investigational Ethenzamide The risk or severity of adverse effects can be increased when Ethenzamide is combined with Ibandronate. Experimental Etodolac The risk or severity of adverse effects can be increased when Etodolac is combined with Ibandronate. Approved, Investigational, Vet Approved Etofenamate The risk or severity of adverse effects can be increased when Etofenamate is combined with Ibandronate. Approved, Investigational Etoricoxib The risk or severity of adverse effects can be increased when Etoricoxib is combined with Ibandronate. Approved, Investigational Evening primrose oil The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Ibandronate. Approved, Investigational Exisulind The risk or severity of adverse effects can be increased when Exisulind is combined with Ibandronate. Investigational Felbinac The risk or severity of adverse effects can be increased when Felbinac is combined with Ibandronate. Experimental Fenbufen The risk or severity of adverse effects can be increased when Fenbufen is combined with Ibandronate. Approved Fenoprofen The risk or severity of adverse effects can be increased when Fenoprofen is combined with Ibandronate. Approved Fentiazac The risk or severity of adverse effects can be increased when Fentiazac is combined with Ibandronate. Experimental Feprazone The risk or severity of adverse effects can be increased when Feprazone is combined with Ibandronate. Experimental Ferulic acid The risk or severity of adverse effects can be increased when Ferulic acid is combined with Ibandronate. Experimental Flecainide Ibandronate may increase the QTc-prolonging activities of Flecainide. Approved, Withdrawn Floctafenine The risk or severity of adverse effects can be increased when Floctafenine is combined with Ibandronate. Approved, Withdrawn Flunixin The risk or severity of adverse effects can be increased when Flunixin is combined with Ibandronate. Vet Approved Flunoxaprofen The risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Ibandronate. Experimental Fluoxetine Ibandronate may increase the QTc-prolonging activities of Fluoxetine. Approved, Vet Approved Flupentixol Ibandronate may increase the QTc-prolonging activities of Flupentixol. Approved, Investigational, Withdrawn Flurbiprofen The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Ibandronate. Approved, Investigational Framycetin Framycetin may increase the hypocalcemic activities of Ibandronate. Approved Gadobenic acid Ibandronate may increase the QTc-prolonging activities of Gadobenic acid. Approved, Investigational Gemifloxacin Ibandronate may increase the QTc-prolonging activities of Gemifloxacin. Approved, Investigational Geneticin Geneticin may increase the hypocalcemic activities of Ibandronate. Experimental Gentamicin Gentamicin may increase the hypocalcemic activities of Ibandronate. Approved, Vet Approved GENTAMICIN C1A GENTAMICIN C1A may increase the hypocalcemic activities of Ibandronate. Experimental Goserelin Ibandronate may increase the QTc-prolonging activities of Goserelin. Approved GPX-150 GPX-150 may increase the hypocalcemic activities of Ibandronate. Investigational Granisetron Ibandronate may increase the QTc-prolonging activities of Granisetron. Approved, Investigational Guacetisal The risk or severity of adverse effects can be increased when Guacetisal is combined with Ibandronate. Experimental Haloperidol Ibandronate may increase the QTc-prolonging activities of Haloperidol. Approved Higenamine The risk or severity of adverse effects can be increased when Higenamine is combined with Ibandronate. Investigational Hydrotalcite The serum concentration of Ibandronate can be decreased when it is combined with Hydrotalcite. Approved, Experimental, Investigational Hygromycin B Hygromycin B may increase the hypocalcemic activities of Ibandronate. Vet Approved Ibuprofen The risk or severity of adverse effects can be increased when Ibuprofen is combined with Ibandronate. Approved Ibuproxam The risk or severity of adverse effects can be increased when Ibuproxam is combined with Ibandronate. Withdrawn Ibutilide Ibandronate may increase the QTc-prolonging activities of Ibutilide. Approved Icatibant The risk or severity of adverse effects can be increased when Icatibant is combined with Ibandronate. Approved, Investigational Idarubicin Idarubicin may increase the hypocalcemic activities of Ibandronate. Approved Iloperidone Ibandronate may increase the QTc-prolonging activities of Iloperidone. Approved Imidazole salicylate The risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Ibandronate. Experimental Indobufen The risk or severity of adverse effects can be increased when Indobufen is combined with Ibandronate. Investigational Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Ibandronate. Approved, Investigational Indoprofen The risk or severity of adverse effects can be increased when Indoprofen is combined with Ibandronate. Withdrawn Iron saccharate The serum concentration of Ibandronate can be decreased when it is combined with Iron saccharate. Approved Isepamicin Isepamicin may increase the hypocalcemic activities of Ibandronate. Experimental Isoxicam The risk or severity of adverse effects can be increased when Isoxicam is combined with Ibandronate. Withdrawn Kanamycin Kanamycin may increase the hypocalcemic activities of Ibandronate. Approved, Investigational, Vet Approved Kebuzone The risk or severity of adverse effects can be increased when Kebuzone is combined with Ibandronate. Experimental Ketoprofen The risk or severity of adverse effects can be increased when Ketoprofen is combined with Ibandronate. Approved, Vet Approved Ketorolac The risk or severity of adverse effects can be increased when Ketorolac is combined with Ibandronate. Approved Lansoprazole The therapeutic efficacy of Ibandronate can be decreased when used in combination with Lansoprazole. Approved, Investigational Leflunomide The risk or severity of adverse effects can be increased when Leflunomide is combined with Ibandronate. Approved, Investigational Lenvatinib Ibandronate may increase the QTc-prolonging activities of Lenvatinib. Approved, Investigational Leuprolide Ibandronate may increase the QTc-prolonging activities of Leuprolide. Approved, Investigational Levofloxacin Ibandronate may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Lisofylline The risk or severity of adverse effects can be increased when Lisofylline is combined with Ibandronate. Investigational Lonazolac The risk or severity of adverse effects can be increased when Lonazolac is combined with Ibandronate. Experimental Lopinavir Ibandronate may increase the QTc-prolonging activities of Lopinavir. Approved Lornoxicam The risk or severity of adverse effects can be increased when Lornoxicam is combined with Ibandronate. Approved, Investigational Loxoprofen The risk or severity of adverse effects can be increased when Loxoprofen is combined with Ibandronate. Approved, Investigational Lumefantrine Ibandronate may increase the QTc-prolonging activities of Lumefantrine. Approved Lumiracoxib The risk or severity of adverse effects can be increased when Lumiracoxib is combined with Ibandronate. Approved, Investigational Magnesium hydroxide The serum concentration of Ibandronate can be decreased when it is combined with Magnesium hydroxide. Approved, Investigational Magnesium oxide The serum concentration of Ibandronate can be decreased when it is combined with Magnesium oxide. Approved Magnesium peroxide The serum concentration of Ibandronate can be decreased when it is combined with Magnesium peroxide. Experimental Magnesium salicylate The serum concentration of Ibandronate can be decreased when it is combined with Magnesium salicylate. Approved Magnesium silicate The serum concentration of Ibandronate can be decreased when it is combined with Magnesium silicate. Approved, Experimental Magnesium sulfate The serum concentration of Ibandronate can be decreased when it is combined with Magnesium sulfate. Approved, Investigational, Vet Approved Magnesium Trisilicate The serum concentration of Ibandronate can be decreased when it is combined with Magnesium Trisilicate. Approved Masoprocol The risk or severity of adverse effects can be increased when Masoprocol is combined with Ibandronate. Approved, Investigational Meclofenamic acid The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ibandronate. Approved, Vet Approved Mefenamic acid The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Ibandronate. Approved Meloxicam The risk or severity of adverse effects can be increased when Meloxicam is combined with Ibandronate. Approved, Vet Approved Mesalazine The risk or severity of adverse effects can be increased when Mesalazine is combined with Ibandronate. Approved Metamizole The risk or severity of adverse effects can be increased when Metamizole is combined with Ibandronate. Approved, Investigational, Withdrawn Methadone Ibandronate may increase the QTc-prolonging activities of Methadone. Approved Metrizamide Metrizamide may increase the hypocalcemic activities of Ibandronate. Approved Micronomicin Micronomicin may increase the hypocalcemic activities of Ibandronate. Experimental Mifepristone Mifepristone may increase the QTc-prolonging activities of Ibandronate. Approved, Investigational Mizoribine The risk or severity of adverse effects can be increased when Mizoribine is combined with Ibandronate. Investigational Mofebutazone The risk or severity of adverse effects can be increased when Mofebutazone is combined with Ibandronate. Experimental Moxifloxacin Ibandronate may increase the QTc-prolonging activities of Moxifloxacin. Approved, Investigational Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Ibandronate. Approved, Investigational Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ibandronate. Approved Nabumetone The risk or severity of adverse effects can be increased when Nabumetone is combined with Ibandronate. Approved Nafamostat The risk or severity of adverse effects can be increased when Nafamostat is combined with Ibandronate. Approved, Investigational Naftifine The risk or severity of adverse effects can be increased when Naftifine is combined with Ibandronate. Approved Naproxen The risk or severity of adverse effects can be increased when Naproxen is combined with Ibandronate. Approved, Vet Approved Neamine Neamine may increase the hypocalcemic activities of Ibandronate. Experimental Neomycin Neomycin may increase the hypocalcemic activities of Ibandronate. Approved, Vet Approved Nepafenac The risk or severity of adverse effects can be increased when Nepafenac is combined with Ibandronate. Approved, Investigational Netilmicin Netilmicin may increase the hypocalcemic activities of Ibandronate. Approved, Investigational Nifenazone The risk or severity of adverse effects can be increased when Nifenazone is combined with Ibandronate. Experimental Niflumic Acid The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Ibandronate. Approved Nilotinib Ibandronate may increase the QTc-prolonging activities of Nilotinib. Approved, Investigational Nimesulide The risk or severity of adverse effects can be increased when Nimesulide is combined with Ibandronate. Approved, Investigational, Withdrawn Nitroaspirin The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Ibandronate. Investigational Ofloxacin Ibandronate may increase the QTc-prolonging activities of Ofloxacin. Approved Olopatadine The risk or severity of adverse effects can be increased when Olopatadine is combined with Ibandronate. Approved Olsalazine The risk or severity of adverse effects can be increased when Olsalazine is combined with Ibandronate. Approved Omeprazole The therapeutic efficacy of Ibandronate can be decreased when used in combination with Omeprazole. Approved, Investigational, Vet Approved Ondansetron Ibandronate may increase the QTc-prolonging activities of Ondansetron. Approved Orgotein The risk or severity of adverse effects can be increased when Orgotein is combined with Ibandronate. Vet Approved Oxaprozin The risk or severity of adverse effects can be increased when Oxaprozin is combined with Ibandronate. Approved Oxyphenbutazone The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Ibandronate. Approved, Withdrawn Paliperidone Ibandronate may increase the QTc-prolonging activities of Paliperidone. Approved Panobinostat Ibandronate may increase the QTc-prolonging activities of Panobinostat. Approved, Investigational Pantoprazole The therapeutic efficacy of Ibandronate can be decreased when used in combination with Pantoprazole. Approved Parecoxib The risk or severity of adverse effects can be increased when Parecoxib is combined with Ibandronate. Approved Paromomycin Paromomycin may increase the hypocalcemic activities of Ibandronate. Approved, Investigational Parthenolide The risk or severity of adverse effects can be increased when Parthenolide is combined with Ibandronate. Approved, Investigational Pazopanib Ibandronate may increase the QTc-prolonging activities of Pazopanib. Approved Pentamidine Ibandronate may increase the QTc-prolonging activities of Pentamidine. Approved, Investigational Perflutren Ibandronate may increase the QTc-prolonging activities of Perflutren. Approved Phenylbutazone The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Ibandronate. Approved, Vet Approved Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ibandronate. Approved, Investigational Pimozide Ibandronate may increase the QTc-prolonging activities of Pimozide. Approved Pirarubicin Pirarubicin may increase the hypocalcemic activities of Ibandronate. Investigational Pirfenidone The risk or severity of adverse effects can be increased when Pirfenidone is combined with Ibandronate. Approved, Investigational Piroxicam The risk or severity of adverse effects can be increased when Piroxicam is combined with Ibandronate. Approved, Investigational Pirprofen The risk or severity of adverse effects can be increased when Pirprofen is combined with Ibandronate. Experimental Plazomicin Plazomicin may increase the hypocalcemic activities of Ibandronate. Investigational Plicamycin Plicamycin may increase the hypocalcemic activities of Ibandronate. Approved, Investigational, Withdrawn Pranoprofen The risk or severity of adverse effects can be increased when Pranoprofen is combined with Ibandronate. Experimental, Investigational Primaquine Ibandronate may increase the QTc-prolonging activities of Primaquine. Approved Procainamide Ibandronate may increase the QTc-prolonging activities of Procainamide. Approved Proglumetacin The risk or severity of adverse effects can be increased when Proglumetacin is combined with Ibandronate. Experimental Promazine Ibandronate may increase the QTc-prolonging activities of Promazine. Approved, Vet Approved Propacetamol The risk or severity of adverse effects can be increased when Propacetamol is combined with Ibandronate. Approved, Investigational Propafenone Ibandronate may increase the QTc-prolonging activities of Propafenone. Approved Propyphenazone The risk or severity of adverse effects can be increased when Propyphenazone is combined with Ibandronate. Experimental Proquazone The risk or severity of adverse effects can be increased when Proquazone is combined with Ibandronate. Experimental PTC299 The risk or severity of adverse effects can be increased when PTC299 is combined with Ibandronate. Investigational Puromycin Puromycin may increase the hypocalcemic activities of Ibandronate. Experimental Quetiapine Ibandronate may increase the QTc-prolonging activities of Quetiapine. Approved Quinidine Ibandronate may increase the QTc-prolonging activities of Quinidine. Approved, Investigational Quinine Ibandronate may increase the QTc-prolonging activities of Quinine. Approved Rabeprazole The therapeutic efficacy of Ibandronate can be decreased when used in combination with Rabeprazole. Approved, Investigational Resveratrol The risk or severity of adverse effects can be increased when Resveratrol is combined with Ibandronate. Approved, Experimental, Investigational Ribostamycin Ribostamycin may increase the hypocalcemic activities of Ibandronate. Approved, Investigational Rofecoxib The risk or severity of adverse effects can be increased when Rofecoxib is combined with Ibandronate. Approved, Investigational, Withdrawn Sabarubicin Sabarubicin may increase the hypocalcemic activities of Ibandronate. Investigational Salicylamide The risk or severity of adverse effects can be increased when Salicylamide is combined with Ibandronate. Approved Salicylic acid The risk or severity of adverse effects can be increased when Salicylic acid is combined with Ibandronate. Approved, Investigational, Vet Approved Salsalate The risk or severity of adverse effects can be increased when Salsalate is combined with Ibandronate. Approved Saquinavir Ibandronate may increase the QTc-prolonging activities of Saquinavir. Approved, Investigational Semapimod The risk or severity of adverse effects can be increased when Semapimod is combined with Ibandronate. Investigational Seratrodast The risk or severity of adverse effects can be increased when Seratrodast is combined with Ibandronate. Approved Serrapeptase The risk or severity of adverse effects can be increased when Serrapeptase is combined with Ibandronate. Investigational Sisomicin Sisomicin may increase the hypocalcemic activities of Ibandronate. Investigational Sotalol Ibandronate may increase the QTc-prolonging activities of Sotalol. Approved SP1049C SP1049C may increase the hypocalcemic activities of Ibandronate. Investigational Spectinomycin Spectinomycin may increase the hypocalcemic activities of Ibandronate. Approved, Investigational, Vet Approved SRT501 The risk or severity of adverse effects can be increased when SRT501 is combined with Ibandronate. Investigational Streptomycin Streptomycin may increase the hypocalcemic activities of Ibandronate. Approved, Vet Approved Streptozocin Streptozocin may increase the hypocalcemic activities of Ibandronate. Approved, Investigational Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Ibandronate. Approved Sulfisoxazole Ibandronate may increase the QTc-prolonging activities of Sulfisoxazole. Approved, Vet Approved Sulindac The risk or severity of adverse effects can be increased when Sulindac is combined with Ibandronate. Approved, Investigational Suprofen The risk or severity of adverse effects can be increased when Suprofen is combined with Ibandronate. Approved, Withdrawn Suxibuzone The risk or severity of adverse effects can be increased when Suxibuzone is combined with Ibandronate. Experimental Tarenflurbil The risk or severity of adverse effects can be increased when Tarenflurbil is combined with Ibandronate. Investigational Technetium Tc-99m oxidronate Ibandronate can cause a decrease in the absorption of Technetium Tc-99m oxidronate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Telavancin Ibandronate may increase the QTc-prolonging activities of Telavancin. Approved Telithromycin Ibandronate may increase the QTc-prolonging activities of Telithromycin. Approved Tenidap The risk or severity of adverse effects can be increased when Tenidap is combined with Ibandronate. Experimental Tenoxicam The risk or severity of adverse effects can be increased when Tenoxicam is combined with Ibandronate. Approved Tepoxalin The risk or severity of adverse effects can be increased when Tepoxalin is combined with Ibandronate. Vet Approved Teriflunomide The risk or severity of adverse effects can be increased when Teriflunomide is combined with Ibandronate. Approved Tetrabenazine Ibandronate may increase the QTc-prolonging activities of Tetrabenazine. Approved, Investigational Thioridazine Ibandronate may increase the QTc-prolonging activities of Thioridazine. Approved, Withdrawn Tiaprofenic acid The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Ibandronate. Approved Tinoridine The risk or severity of adverse effects can be increased when Tinoridine is combined with Ibandronate. Investigational Tobramycin Tobramycin may increase the hypocalcemic activities of Ibandronate. Approved, Investigational Tolfenamic Acid The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Ibandronate. Approved, Investigational Tolmetin The risk or severity of adverse effects can be increased when Tolmetin is combined with Ibandronate. Approved Toremifene Ibandronate may increase the QTc-prolonging activities of Toremifene. Approved, Investigational Tranilast The risk or severity of adverse effects can be increased when Tranilast is combined with Ibandronate. Approved, Investigational Tribenoside The risk or severity of adverse effects can be increased when Tribenoside is combined with Ibandronate. Experimental Triptolide The risk or severity of adverse effects can be increased when Triptolide is combined with Ibandronate. Investigational Tromethamine The serum concentration of Ibandronate can be decreased when it is combined with Tromethamine. Approved Valdecoxib The risk or severity of adverse effects can be increased when Valdecoxib is combined with Ibandronate. Approved, Investigational, Withdrawn Valrubicin Valrubicin may increase the hypocalcemic activities of Ibandronate. Approved Vandetanib Ibandronate may increase the QTc-prolonging activities of Vandetanib. Approved Vemurafenib Ibandronate may increase the QTc-prolonging activities of Vemurafenib. Approved Zaltoprofen The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Ibandronate. Approved, Investigational Zileuton The risk or severity of adverse effects can be increased when Zileuton is combined with Ibandronate. Approved, Investigational, Withdrawn Ziprasidone Ibandronate may increase the QTc-prolonging activities of Ziprasidone. Approved Zomepirac The risk or severity of adverse effects can be increased when Zomepirac is combined with Ibandronate. Withdrawn Zoptarelin doxorubicin Zoptarelin doxorubicin may increase the hypocalcemic activities of Ibandronate. Investigational Zorubicin Zorubicin may increase the hypocalcemic activities of Ibandronate. Experimental Zuclopenthixol Ibandronate may increase the QTc-prolonging activities of Zuclopenthixol. Approved, Investigational - Food Interactions
- Take on an empty stomach. All foods markedly reduce (up to 90%) ibandronate bioavailabilty. Take with plain water (not mineralized) at least 1 hour before any food. Bioavailability and effect on bone density are both impaired if the patient eats or drinks in less than 1 hour after taking this product. Drink a large glass of water and stay in an upright position for at least 60 minutes after taking this product.
References
- Synthesis Reference
Revital Lifshitz-Liron, Thomas Bayer, Judith Aronhime, Michael Pinchasov, "Solid and crystalline ibandronate sodium and processes for preparation thereof." U.S. Patent US20070179119, issued August 02, 2007.
US20070179119- General References
- Epstein S, Zaidi M: Biological properties and mechanism of action of ibandronate: application to the treatment of osteoporosis. Bone. 2005 Oct;37(4):433-40. [PubMed:16046205]
- External Links
- Human Metabolome Database
- HMDB0014848
- PubChem Compound
- 60852
- PubChem Substance
- 46508134
- ChemSpider
- 54839
- BindingDB
- 12577
- ChEMBL
- CHEMBL997
- Therapeutic Targets Database
- DAP001022
- PharmGKB
- PA10270
- HET
- BFQ
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Ibandronate
- ATC Codes
- M05BA06 — Ibandronic acid
- PDB Entries
- 2f94 / 4umj
- FDA label
- Download (296 KB)
- MSDS
- Download (16 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Hoffmann la roche inc
- Packagers
- Diversified Healthcare Services Inc.
- F Hoffmann La Roche Ltd.
- F Hoffmann-La Roche Ltd.
- Physicians Total Care Inc.
- Vetter Pharma Fertigung GmbH and Co. KG
- Dosage forms
Form Route Strength Injection, solution Intravenous 3 mg Tablet, film coated Oral 150 mg Liquid Intravenous 1 mg Tablet, film coated Oral 150 mg/1 Injection, solution, concentrate Intravenous 1 mg Injection, solution, concentrate Intravenous 2 mg Injection, solution, concentrate Intravenous 6 mg Tablet, film coated Oral 50 mg Injection Intravenous 3 mg/3mL Injection, solution Intravenous 3 mg/3mL Tablet Oral 150 mg/1 - Prices
Unit description Cost Unit Boniva 3 mg/3ml Kit Box 524.22USD box Boniva 3 mg/3 ml syringe 504.06USD syringe Boniva 3 150 mg tablet Disp Pack 388.93USD disp Boniva 150 mg tablet 124.66USD tablet Boniva 2.5 mg tablet 4.16USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) US4927814 No 1995-03-17 2012-03-17 US CA2346662 No 2006-05-09 2019-10-01 Canada US7192938 Yes 2003-11-06 2023-11-06 US US7718634 Yes 2003-11-06 2023-11-06 US US7410957 No 2003-05-06 2023-05-06 US US6294196 No 1999-10-07 2019-10-07 US US6143326 No 1997-04-21 2017-04-21 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source water solubility Freely soluble Not Available logP -2.1 Not Available - Predicted Properties
Property Value Source Water Solubility 13.4 mg/mL ALOGPS logP 0.26 ALOGPS logP -2.5 ChemAxon logS -1.4 ALOGPS pKa (Strongest Acidic) 0.66 ChemAxon pKa (Strongest Basic) 9.93 ChemAxon Physiological Charge -1 ChemAxon Hydrogen Acceptor Count 8 ChemAxon Hydrogen Donor Count 5 ChemAxon Polar Surface Area 138.53 Å2 ChemAxon Rotatable Bond Count 9 ChemAxon Refractivity 71.16 m3·mol-1 ChemAxon Polarizability 29.51 Å3 ChemAxon Number of Rings 0 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption - 0.9664 Blood Brain Barrier - 0.5229 Caco-2 permeable - 0.6012 P-glycoprotein substrate Substrate 0.6888 P-glycoprotein inhibitor I Non-inhibitor 0.8195 P-glycoprotein inhibitor II Non-inhibitor 0.9838 Renal organic cation transporter Non-inhibitor 0.9092 CYP450 2C9 substrate Non-substrate 0.8376 CYP450 2D6 substrate Non-substrate 0.7863 CYP450 3A4 substrate Non-substrate 0.5504 CYP450 1A2 substrate Non-inhibitor 0.832 CYP450 2C9 inhibitor Non-inhibitor 0.8159 CYP450 2D6 inhibitor Non-inhibitor 0.8987 CYP450 2C19 inhibitor Non-inhibitor 0.8045 CYP450 3A4 inhibitor Non-inhibitor 0.8901 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9945 Ames test Non AMES toxic 0.6527 Carcinogenicity Non-carcinogens 0.683 Biodegradation Not ready biodegradable 0.8346 Rat acute toxicity 2.4278 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.6061 hERG inhibition (predictor II) Non-inhibitor 0.6622
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as bisphosphonates. These are organic compounds containing two phosphonate groups linked together through a carbon atoms.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Organic phosphonic acids and derivatives
- Sub Class
- Bisphosphonates
- Direct Parent
- Bisphosphonates
- Alternative Parents
- Organic phosphonic acids / 1,3-aminoalcohols / Trialkylamines / Organopnictogen compounds / Organophosphorus compounds / Organooxygen compounds / Organic oxides / Hydrocarbon derivatives
- Substituents
- Bisphosphonate / Organophosphonic acid / 1,3-aminoalcohol / Tertiary aliphatic amine / Tertiary amine / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound / Organic oxide / Hydrocarbon derivative
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- Not Available
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Poly(a) rna binding
- Specific Function
- Key enzyme in isoprenoid biosynthesis which catalyzes the formation of farnesyl diphosphate (FPP), a precursor for several classes of essential metabolites including sterols, dolichols, carotenoids...
- Gene Name
- FDPS
- Uniprot ID
- P14324
- Uniprot Name
- Farnesyl pyrophosphate synthase
- Molecular Weight
- 48275.03 Da
References
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Chapurlat RD, Delmas PD: Drug insight: Bisphosphonates for postmenopausal osteoporosis. Nat Clin Pract Endocrinol Metab. 2006 Apr;2(4):211-9; quiz following 238. [PubMed:16932286]
- Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001 Feb;296(2):235-42. [PubMed:11160603]
- Rondeau JM, Bitsch F, Bourgier E, Geiser M, Hemmig R, Kroemer M, Lehmann S, Ramage P, Rieffel S, Strauss A, Green JR, Jahnke W: Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs. ChemMedChem. 2006 Feb;1(2):267-73. [PubMed:16892359]
Yes
Antagonist
References
- Jahnke W, Henry C: An in vitro assay to measure targeted drug delivery to bone mineral. ChemMedChem. 2010 May 3;5(5):770-6. doi: 10.1002/cmdc.201000016. [PubMed:20209564]
- Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH: Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006 May;38(5):617-27. Epub 2005 Jul 20. [PubMed:16046206]
Drug created on June 13, 2005 07:24 / Updated on March 02, 2018 05:05